RT Journal Article
SR Electronic
T1 Simultaneous Detection and HER2 Profiling of Circulating Breast Cancer Cells in Clinical Patients Using a Rare Cell Sorter
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4879
OP 4886
DO 10.21873/anticanres.15993
VO 42
IS 10
A1 MORI, TOMOKO
A1 FURUKAWA, ATSUKO
A1 BILAL, TURAN
A1 UEDA, AYA
A1 BANDO, HIROKO
A1 MASUDA, TAISUKE
A1 ARAI, FUMIHITO
A1 MATSUSAKA, SATOSHI
YR 2022
UL http://ar.iiarjournals.org/content/42/10/4879.abstract
AB Background/Aim: This study describes a rare cell sorter (RCS) method to detect circulating tumor cells (CTCs) and CTC clusters in whole blood without pretreatment. Patients and Methods: We collected samples from breast cancer patients at the University of Tsukuba Hospital. A total of 15 whole-blood specimens from patients with breast cancer were collected and analyzed via a microfluidics chip, fluorescence-conjugated antibody staining, and fluorescence microscopy. Of 15 total cases, eight were analyzed by RCS ver3 and seven were analyzed by RCS ver3.5 to reveal potential clinical differences in scanning methods. We then examined the HER2 status on 4 of the 15 patients using our RCS system. Results: RCS efficiently detected all subtypes of CTCs and CTC clusters from the peripheral blood of cancer patients. The concordance rate of HER2 status between tissue and CTCs in 4 tested clinical samples was 100%. Conclusion: RCS is a non-invasive method that allows for simultaneous detection of CTCs, cluster presence, and surface marker (e.g., HER2) status. Frequent sampling is, thus, possible and the large amount of data obtained will be clinically useful to predict response to therapy as well as plan adjunct support therapies in cancer patients.